Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America
Objective: This study aimed to investigate the role and prognosis of Alzheimer disease biomarkers in patients with mild cognitive impairment (MCI) at a memory clinic in Latin America. Methods: We studied 89 patients with MCI, 43 with Alzheimer-type dementia, and 18 healthy controls (matched for age,...
- Autores:
-
Allegri, Ricardo F.
Chrem Méndez, Patricio
Russo, María Julieta
Cohen, Gabriela
Calandri, Ismael Luis
Campos, Jorge A.
Nahas, Federico E.
Surace, Ezequiel I.
Vázquez, Silvia E.
Sevlever, G. E.
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2018
- Institución:
- Corporación Universidad de la Costa
- Repositorio:
- REDICUC - Repositorio CUC
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.cuc.edu.co:11323/3320
- Acceso en línea:
- https://hdl.handle.net/11323/3320
https://repositorio.cuc.edu.co/
- Palabra clave:
- Alzheimer
Amyloid
Biomarker
Mild cognitive impairment
Neurodegeneration
Amiloide
Biomarcador
Deterioro cognitivo leve
Neurodegeneración
- Rights
- openAccess
- License
- Attribution-NonCommercial-ShareAlike 4.0 International
id |
RCUC2_b12451fe14eaa8a264949777da93ba26 |
---|---|
oai_identifier_str |
oai:repositorio.cuc.edu.co:11323/3320 |
network_acronym_str |
RCUC2 |
network_name_str |
REDICUC - Repositorio CUC |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America |
dc.title.translated.spa.fl_str_mv |
Biomarcadores de enfermedad de Alzheimer en deterioro cognitivo leve: experiencia en una clínica de memoria de Latinoamérica |
title |
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America |
spellingShingle |
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America Alzheimer Amyloid Biomarker Mild cognitive impairment Neurodegeneration Amiloide Biomarcador Deterioro cognitivo leve Neurodegeneración |
title_short |
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America |
title_full |
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America |
title_fullStr |
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America |
title_full_unstemmed |
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America |
title_sort |
Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America |
dc.creator.fl_str_mv |
Allegri, Ricardo F. Chrem Méndez, Patricio Russo, María Julieta Cohen, Gabriela Calandri, Ismael Luis Campos, Jorge A. Nahas, Federico E. Surace, Ezequiel I. Vázquez, Silvia E. Sevlever, G. E. |
dc.contributor.author.spa.fl_str_mv |
Allegri, Ricardo F. Chrem Méndez, Patricio Russo, María Julieta Cohen, Gabriela Calandri, Ismael Luis Campos, Jorge A. Nahas, Federico E. Surace, Ezequiel I. Vázquez, Silvia E. Sevlever, G. E. |
dc.subject.spa.fl_str_mv |
Alzheimer Amyloid Biomarker Mild cognitive impairment Neurodegeneration Amiloide Biomarcador Deterioro cognitivo leve Neurodegeneración |
topic |
Alzheimer Amyloid Biomarker Mild cognitive impairment Neurodegeneration Amiloide Biomarcador Deterioro cognitivo leve Neurodegeneración |
description |
Objective: This study aimed to investigate the role and prognosis of Alzheimer disease biomarkers in patients with mild cognitive impairment (MCI) at a memory clinic in Latin America. Methods: We studied 89 patients with MCI, 43 with Alzheimer-type dementia, and 18 healthy controls (matched for age, sex, and educational level) at our memory clinic (Instituto FLENI) in Buenos Aires, Argentina. Patients and controls underwent an extensive demographic, neurological, and neuropsychological assessment. All subjects underwent a brain MRI scan; FDG-PET scan; amyloid PET scan; apolipoprotein E genotyping; and cerebrospinal fluid concentrations of Aβ1-42, tau, and phosphorylated tau. Patients were categorised as positive or negative for the presence of amyloid pathology and neurodegeneration. Results: Amyloid pathology was observed in cerebrospinal fluid results in 18% of controls, 64% of patients with MCI, and 92% of patients with Alzheimer-type dementia. Suspected non–Alzheimer disease pathophysiology was found in 11% of controls, 6% of patients with MCI, and 8% of patients with Alzheimer-type dementia. At 30 months of follow-up, 45% of amyloid-positive patients with MCI and 20% of amyloid-negative patients with MCI showed progression to dementia. Conclusions: This study demonstrates biomarker-based MCI prognosis and supports its role in clinical decision-making in daily practice. |
publishDate |
2018 |
dc.date.issued.none.fl_str_mv |
2018-04-14 |
dc.date.accessioned.none.fl_str_mv |
2019-05-14T13:06:20Z |
dc.date.available.none.fl_str_mv |
2019-05-14T13:06:20Z |
dc.type.spa.fl_str_mv |
Artículo de revista |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.content.spa.fl_str_mv |
Text |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/acceptedVersion |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
acceptedVersion |
dc.identifier.issn.spa.fl_str_mv |
02134853 |
dc.identifier.uri.spa.fl_str_mv |
https://hdl.handle.net/11323/3320 |
dc.identifier.instname.spa.fl_str_mv |
Corporación Universidad de la Costa |
dc.identifier.reponame.spa.fl_str_mv |
REDICUC - Repositorio CUC |
dc.identifier.repourl.spa.fl_str_mv |
https://repositorio.cuc.edu.co/ |
identifier_str_mv |
02134853 Corporación Universidad de la Costa REDICUC - Repositorio CUC |
url |
https://hdl.handle.net/11323/3320 https://repositorio.cuc.edu.co/ |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.rights.spa.fl_str_mv |
Attribution-NonCommercial-ShareAlike 4.0 International |
dc.rights.uri.spa.fl_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
rights_invalid_str_mv |
Attribution-NonCommercial-ShareAlike 4.0 International http://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.publisher.spa.fl_str_mv |
Universidad de la Costa |
institution |
Corporación Universidad de la Costa |
bitstream.url.fl_str_mv |
https://repositorio.cuc.edu.co/bitstreams/1a389e09-b097-432e-bf26-d09c5c769f68/download https://repositorio.cuc.edu.co/bitstreams/7bfe9fa3-2054-464a-a370-adab0439bb8c/download https://repositorio.cuc.edu.co/bitstreams/2065c769-163c-4ccd-94cf-bcd370d5425e/download https://repositorio.cuc.edu.co/bitstreams/00d25772-6e54-481a-9a11-e5ec45290525/download https://repositorio.cuc.edu.co/bitstreams/c7c9209b-8065-4baf-8cb0-1f7e351e41fe/download |
bitstream.checksum.fl_str_mv |
724241c63a31ed3e43c0f3461fde9c08 934f4ca17e109e0a05eaeaba504d7ce4 8a4605be74aa9ea9d79846c1fba20a33 0b098906adf8a0c0df5a7a2a54037fe9 b2ffef7c30d7a585a78d64b32e8bcd8a |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio de la Universidad de la Costa CUC |
repository.mail.fl_str_mv |
repdigital@cuc.edu.co |
_version_ |
1811760750329331712 |
spelling |
Allegri, Ricardo F.Chrem Méndez, PatricioRusso, María JulietaCohen, GabrielaCalandri, Ismael LuisCampos, Jorge A.Nahas, Federico E.Surace, Ezequiel I.Vázquez, Silvia E.Sevlever, G. E.2019-05-14T13:06:20Z2019-05-14T13:06:20Z2018-04-1402134853https://hdl.handle.net/11323/3320Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Objective: This study aimed to investigate the role and prognosis of Alzheimer disease biomarkers in patients with mild cognitive impairment (MCI) at a memory clinic in Latin America. Methods: We studied 89 patients with MCI, 43 with Alzheimer-type dementia, and 18 healthy controls (matched for age, sex, and educational level) at our memory clinic (Instituto FLENI) in Buenos Aires, Argentina. Patients and controls underwent an extensive demographic, neurological, and neuropsychological assessment. All subjects underwent a brain MRI scan; FDG-PET scan; amyloid PET scan; apolipoprotein E genotyping; and cerebrospinal fluid concentrations of Aβ1-42, tau, and phosphorylated tau. Patients were categorised as positive or negative for the presence of amyloid pathology and neurodegeneration. Results: Amyloid pathology was observed in cerebrospinal fluid results in 18% of controls, 64% of patients with MCI, and 92% of patients with Alzheimer-type dementia. Suspected non–Alzheimer disease pathophysiology was found in 11% of controls, 6% of patients with MCI, and 8% of patients with Alzheimer-type dementia. At 30 months of follow-up, 45% of amyloid-positive patients with MCI and 20% of amyloid-negative patients with MCI showed progression to dementia. Conclusions: This study demonstrates biomarker-based MCI prognosis and supports its role in clinical decision-making in daily practice.Objetivo: este estudio tuvo como objetivo investigar el papel y el pronóstico de los biomarcadores de la enfermedad de Alzheimer en pacientes con deterioro cognitivo leve (MCI) en una clínica de memoria en América Latina. Métodos: Estudiamos 89 pacientes con LM, 43 con demencia de tipo Alzheimer y 18 controles sanos (emparejados por edad, sexo y nivel educativo) en nuestra clínica de memoria (Instituto FLENI) en Buenos Aires, Argentina. Los pacientes y los controles se sometieron a una extensa evaluación demográfica, neurológica y neuropsicológica. Todos los sujetos se sometieron a una resonancia magnética cerebral; FDG-PET scan; tomografía PET amiloide; apolipoproteína E genotipado; y concentraciones de líquido cefalorraquídeo de Aβ1-42, tau y tau fosforilada. Los pacientes fueron categorizados como positivos o negativos por la presencia de patología amiloide y neurodegeneración. Resultados: se observó patología de amiloide en los resultados del líquido cefalorraquídeo en el 18% de los controles, el 64% de los pacientes con LM y el 92% de los pacientes con demencia de tipo Alzheimer. La sospecha de fisiopatología no relacionada con la enfermedad de Alzheimer se encontró en el 11% de los controles, el 6% de los pacientes con MCI y el 8% de los pacientes con demencia de tipo Alzheimer. A los 30 meses de seguimiento, el 45% de los pacientes con amiloide positivo con MCI y el 20% de los pacientes con amiloide negativo con MCI mostraron progresión a demencia. Conclusiones: este estudio demuestra el pronóstico de MCI basado en biomarcadores y apoya su papel en la toma de decisiones clínicas en la práctica diaria.Allegri, Ricardo F.-32401e5a-217d-458d-846f-9d361c8b020e-0Chrem Méndez, Patricio-e85d4384-3d18-4c2c-b3eb-d4dbc6a2a6a8-0Russo, María Julieta-77886bc5-e0df-4bc1-acfc-7d4a5e5a1dc6-0Cohen, Gabriela-b3a47e48-a3ef-456e-a814-8795b360c90c-0Calandri, Ismael Luis-b614c669-ee2e-467e-8179-1b5cc9badf9b-0Campos, Jorge A.-28d553d5-021d-4ee6-b46e-f3fb496bdae4-0Nahas, Federico E.-22e2f65e-bd51-484d-813d-f396104fc1b8-0Surace, Ezequiel I.-4d93de5d-1bca-4dd0-a400-ec2693b722c0-0Vázquez, Silvia E.-cdd1b025-6bd4-49dd-b074-acd901b2314e-0Sevlever, G. E.-5887388a-0d69-4a9d-9d64-15f5783214a3-0engUniversidad de la CostaAttribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2AlzheimerAmyloidBiomarkerMild cognitive impairmentNeurodegenerationAmiloideBiomarcadorDeterioro cognitivo leveNeurodegeneraciónBiomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin AmericaBiomarcadores de enfermedad de Alzheimer en deterioro cognitivo leve: experiencia en una clínica de memoria de LatinoaméricaArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/acceptedVersionPublicationORIGINALBIOMARKERS OF ALZHEIMER.pdfBIOMARKERS OF ALZHEIMER.pdfapplication/pdf114938https://repositorio.cuc.edu.co/bitstreams/1a389e09-b097-432e-bf26-d09c5c769f68/download724241c63a31ed3e43c0f3461fde9c08MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81031https://repositorio.cuc.edu.co/bitstreams/7bfe9fa3-2054-464a-a370-adab0439bb8c/download934f4ca17e109e0a05eaeaba504d7ce4MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.cuc.edu.co/bitstreams/2065c769-163c-4ccd-94cf-bcd370d5425e/download8a4605be74aa9ea9d79846c1fba20a33MD53THUMBNAILBIOMARKERS OF ALZHEIMER.pdf.jpgBIOMARKERS OF ALZHEIMER.pdf.jpgimage/jpeg49924https://repositorio.cuc.edu.co/bitstreams/00d25772-6e54-481a-9a11-e5ec45290525/download0b098906adf8a0c0df5a7a2a54037fe9MD55TEXTBIOMARKERS OF ALZHEIMER.pdf.txtBIOMARKERS OF ALZHEIMER.pdf.txttext/plain1850https://repositorio.cuc.edu.co/bitstreams/c7c9209b-8065-4baf-8cb0-1f7e351e41fe/downloadb2ffef7c30d7a585a78d64b32e8bcd8aMD5611323/3320oai:repositorio.cuc.edu.co:11323/33202024-09-17 10:57:45.281http://creativecommons.org/licenses/by-nc-sa/4.0/Attribution-NonCommercial-ShareAlike 4.0 Internationalopen.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.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 |